ID: h-c9b96e0e3b
Hypothesis
Rab12 may better report chronic lysosomal stress biology than Rab10 in G2019S contexts
The strongest biomarker-oriented hypothesis is not that Rab12 is the main pathogenic target, but that pRab12 may outperform pRab10 as a translational readout under chronic lysosomal stress or disease-relevant compartmentalization.
EvidencePending (0%)📖 6 cit🗣 1 debates✓ 6 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
The strongest biomarker-oriented hypothesis is not that Rab12 is the main pathogenic target, but that pRab12 may outperform pRab10 as a translational readout under chronic lysosomal stress or disease-relevant compartmentalization. This could reflect substrate usage, compartment retention, or reduced phosphatase masking, making paired pRab12:pRab10 measurements more informative than either alone.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["RAB12<br/>Primary Target"]
B["Biological Process 1<br/>Mechanistic Step A"]
C["Biological Process 2<br/>Mechanistic Step B"]
D["Output Phenotype<br/>Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix6 supports2 contradicts
Supports
Human PBMC data support elevated pS106-Rab12 in G2019S carriers, suggesting Rab12 may be a useful translational biomarker.
Supports
pRab12 accumulates in lysosome-like granulovacuolar structures in neurodegenerative brain tissue, including G2019S-linked disease.
Supports
Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis.
Supports
Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.
Supports
RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes.
Supports
LRRK2-mediated phosphorylation and thermal stability of Rab12 are regulated by bound nucleotides.
Contradicts
Biomarker superiority in blood does not prove mutation-dependent substrate switching during chronic swelling in disease-relevant cells.
Contradicts
Rab12 prominence may reflect phosphatase opposition or assay behavior rather than true mechanistic preference.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — RAB12
No curated PDB or AlphaFold mapping for RAB12 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for RAB12 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for RAB12.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 1.0%
Volatility
Low
0.0036
Events (7d)
3
Price History
▼13.3%💾 Resource Usage
LLM Tokens
18,998
$0.0570
Total Cost
$0.0570
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we stratify G2019S LRRK2 mutation carriers into manifest (PD-diagnosed) and non-manifest groups, THEN CSF or plasma pRab12 levels will show a larger effect size (Cohen's d > 0.5) for distinguishing | pRab12 will demonstrate superior sensitivity and specificity for identifying phenoconversion or disease severity (MDS-UPDRS III) with AUC > 0.75 versus pRab10 A | — no observation — | pending | 0.65 |
| IF we expose G2019S patient-derived dopaminergic neurons or LRRK2 G2019S knock-in mice to lysosomal stress (chloroquine 20 mg/kg i.p. for 5 days) or LRRK2 kinase inhibition (MLi-2 10 mg/kg for 14 days | pRab12 phosphorylation will change by ≥ 100% from baseline under both conditions, whereas pRab10 will change by < 50%. | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we stratify G2019S LRRK2 mutation carriers into manifest (PD-diagnosed) and non-manifest groups, THEN CSF or plasma pRab12 levels will show a larger effect size (Cohen's d > 0.5) for distinguishing manifest from non-manifest carriers compared to pRab10 levels within 6 months of enrollment.
Predicted outcome: pRab12 will demonstrate superior sensitivity and specificity for identifying phenoconversion or disease severity (MDS-UPDRS III) with AUC > 0.75 versu
Falsification: pRab10 achieves equal or greater effect size (Cohen's d ≥ pRab12) or AUC for manifest vs. non-manifest stratification, or both biomarkers fail to distinguish groups (p > 0.05).
pendingconf 55%
IF we expose G2019S patient-derived dopaminergic neurons or LRRK2 G2019S knock-in mice to lysosomal stress (chloroquine 20 mg/kg i.p. for 5 days) or LRRK2 kinase inhibition (MLi-2 10 mg/kg for 14 days), THEN pRab12 will show a ≥ 2-fold greater dynamic range (percent change from baseline) compared to
Predicted outcome: pRab12 phosphorylation will change by ≥ 100% from baseline under both conditions, whereas pRab10 will change by < 50%.
Falsification: pRab10 exhibits equal or greater fold-change from baseline compared to pRab12 under either condition (difference < 50%), or neither phospho-Rab shows significant change (p > 0.05, n ≥ 6 per group).
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.